Forge Biologics Announces Closing of $120 Million Series B Financing
29.4.2021 15:00:00 EEST | Business Wire | Press release
Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced the closing of a $120 million Series B financing. The financing was led by RA Capital Management with participation from Perceptive Advisors and related affiliates, Surveyor Capital (a Citadel company), Octagon Capital, and Marshall Wace. Existing investors Perceptive Xontogeny Venture Fund and Drive Capital also participated. In connection with the financing, Matthew Hammond, Ph.D., of RA Capital, and Fred Callori of the Perceptive Xontogeny Venture Fund will join the Company’s Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210429005365/en/
“We are very pleased to be working with RA Capital and a strong syndicate of top-tier life sciences investors who share our vision as we now advance our growth as a global gene therapy manufacturing and development company,” said Timothy J. Miller, Ph.D., CEO, President and Co-Founder of Forge Biologics. “We have built Forge into a focused gene therapy development engine with a firm commitment to helping our clients provide potentially life-saving gene therapies to patients. We believe that focusing entirely on gene therapy will allow us to best serve our clients and patients by efficiently delivering high quality product.”
Forge will use the proceeds of this Series B financing to accelerate the expansion of its AAV manufacturing CDMO capabilities with cGMP production capacity, as well as operate its subsidiaries that are advancing novel AAV gene therapy programs. Forge brings a patients-first approach to accelerate the development of transformative medicines for those who need them most and is addressing the growing demand for gene therapy manufacturing capacity. Through its currently-operational 175,000 square foot cGMP facility in Columbus, Ohio, dedicated to AAV viral vector manufacturing, Forge offers end-to-end manufacturing services, including research and toxicology grade AAV production, to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing.
“The success of complex biologics like AAV is exhausting existing manufacturing capacity around the industry. This financing will help to address this industry-wide capacity shortage by properly capitalizing an emerging gene therapy-focused CDMO capable of producing high quality cGMP product for its clients,” said Matthew Hammond, Ph.D., principal at RA Capital Management. “We are confident that Forge’s experienced team will become the trusted partner of innovative therapeutics companies, working collaboratively with clients to successfully deliver AAV manufacturing solutions.”
Through its subsidiaries, Forge is also working to advance a proprietary pipeline of novel gene therapies, including its lead program FBX-101 for the treatment of patients with Krabbe disease, a first-in-human gene therapy utilizing an adeno-associated virus (AAV) to deliver a functioning copy of the GALC gene intravenously to cells in the central nervous system (CNS) and peripheral organs.
Chardan Capital Markets acted as exclusive placement agent for the offering, with Ice Miller acting as legal advisor.
About Forge Biologics
Forge Biologics is a hybrid gene therapy contract manufacturing and therapeutic development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea into reality. Forge has a 175,000 square foot facility in Columbus, Ohio, “The Hearth,” to serve as its headquarters. The Hearth is the home of a custom-designed cGMP facility dedicated to AAV viral vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most.
For more information, please visit https://www.forgebiologics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210429005365/en/
Contact information
Media Inquiries:
Dan Salvo
Director of Communications and Community Development
Forge Biologics Inc.
media@forgebiologics.com
Business Development:
Magdalena Tyrpien
Vice President and Head of Business Development
Forge Biologics Inc.
BD@forgebiologics.com
Investor Relations
Christina Perry, MSA, CPA
Vice President, Finance and Investor Relations
Forge Biologics Inc.
Investors@forgebiologics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Klarna Launches Consumer FX: Shop From Klarna Merchants Worldwide, Regardless of Currency21.10.2026 15:47:00 EEST | Press release
Klarna Group Plc (NYSE: KLAR), the everyday finance network, today launched Consumer FX, which allows shoppers to buy from any participating Klarna merchant in the world and pay in their own currency, with no exchange fee. The price and rate are shown upfront and stay visible in the Klarna app after purchase, so there are no surprises on the statement. The new launch means any Klarna connected merchant can sell to Klarna’s 120 million consumers in 26 countries with no new integration, and no need for a local entity of foreign bank account. Klarna also handles FX disclosure, consent and compliance. Early results show merchants gain a 5% lift in conversion and 6% in sales due to the expanded reach. The launch comes as cross-border payments are growing globally. DHL reports that 70% of 2026 shoppers buy internationally, up 10% from 2025, and 45% buy across borders more than once a month.1 “Increasingly, shoppers aren’t thinking in borders,” says David Sykes, Chief Commercial Officer, Klar
Merck Collaborates with NVIDIA, Microsoft and Dawn Health to Develop Novel Support Model for People Living with Rare Tumors21.10.2026 15:35:00 EEST | Press release
Merck, a leading science and technology company, today announced a collaboration with NVIDIA Corporation (Santa Clara, California, USA), Microsoft Corporation (Redmond, Washington, USA) and Dawn Health A/S (Copenhagen, Denmark) to build an innovative model for Patient Support Programs (PSPs). The four-way collaboration brings together pharmaceutical and clinical expertise, enterprise technology, AI services and digital health product design, with the shared goal of making specialist-level support more individualized, responsive and continuously available to patients, no matter how complex their treatment journey is. “Across their treatment journeys, patients with rare tumors often describe challenges that extend well beyond clinical care, like navigating multiple specialists, complex regimens and repeatedly reconstructing their treatment story for each new stakeholder. Our integrated support ecosystem starts with the need. The goal is to truly transform how healthcare is experienced, n
Corpay Cross-Border Named the Official FX Partner of Newcastle United21.10.2026 15:30:00 EEST | Press release
Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into a multi-year agreement with Newcastle United to become their Official Foreign Exchange (FX) Partner. Through this partnership, Corpay Cross-Border will deliver comprehensive FX risk management solutions to support Newcastle United’s day-to-day business operations. In addition, its award-winning platform will enable the club to manage global payments seamlessly through a single point of access. “We’re thrilled to be named the Official FX Partner of Newcastle United, one of the Premier League’s most iconic and ambitious clubs,” said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “This partnership further strengthens Corpay’s position as the trusted corporate payments and currency risk management provider of choice across the Premier League. We look forward to supporting the club throughout what promises to be an exciting seaso
Insight Named an OpenAI Advanced Partner to Accelerate Midmarket Enterprise AI Adoption21.10.2026 15:28:00 EEST | Press release
Insight Enterprises (NASDAQ: NSIT) today announced that it has been named an OpenAI Advanced Partner within the OpenAI Partner Network, reinforcing Insight's position as a provider of AI solutions for midmarket and lower-enterprise organisations seeking to accelerate AI adoption. As part of the expanded relationship, Insight will work with OpenAI to help organisations build, deploy and scale AI solutions responsibly and effectively. The expanded relationship reflects Insight's experience helping organisations successfully deploy and scale AI. “Insight has built a repeatable approach that connects technology, process transformation, and workforce adoption so clients can move from pilots to production and results faster,” said Jack Azagury, Insight President and CEO. “As an OpenAI Advanced Partner, we can help more organisations deploy AI responsibly, scale across the enterprise, and realise value at speed.” Combining OpenAI's frontier models and products with Insight's expertise in AI,
TreviPay Expands Pay by Invoice Availability for Walmart Business Customers21.10.2026 15:00:00 EEST | Press release
TreviPay, a global B2B payments infrastructure partner, today announced the general availability of Pay By Invoice for eligible Walmart Business customers. Following an initial pilot, the expanded availability gives more organizations a new way to manage purchasing and payments online and in Walmart stores. Walmart Business Pay By Invoice provides net 30-day terms, a dedicated business line of credit and detailed invoicing built into the Walmart Business purchasing experience. Powered by TreviPay, Walmart Business Pay By Invoice is designed to give organizations greater flexibility in how they manage business purchases and payments. Eligible customers can get what they need and pay on net 30-day terms, helping them preserve cash flow for other priorities while keeping operations moving. Purchasing controls and payment reconciliation also help organizations share purchasing responsibilities while maintaining oversight and keeping purchase activity, invoices, payments, returns and refund
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom